ObsEva SA (NASDAQ:OBSV) is moving slightly lower in the pre-market session after the news on Wednesday.
ObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021
- announced the presentation of clinical data from the PROLONG Phase 2a proof-of-concept study of ebopiprant for spontaneous preterm labor at the Royal College of Obstetricians and Gynaecologists (RCOG) Virtual World Congress 2021, being held June 9-12. Ebopiprant is ObsEva’s first in class, orally active selective prostaglandin F2α (PGF2α) receptor antagonist designed to treat preterm labor.
- Details of the oral presentation are as follows: Title: A Randomised, Placebo-Controlled, Proof-of-Concept Trial of Ebopiprant for Spontaneous Preterm Labor (PROLONG) – Abstract ID: 601
- Presenter: Ben Mol, Ph.D., M.D., Professor of Obstetrics and Gynaecology, Monash Medical Centre, Melbourne Australia- Session Date: Saturday, June 12, 2021- Session Time: 8:10-8:20 a.m. Greenwich Mean Time
Market Action
As of 7:23, OBSV stock went down 0.69% to $2.87. So far the stock has traded 1.7K shares traded hands.
 Is In News){kind=link}